Archive - The Oncology Shot with Timothee Olivier

Aging Out of Evidence: Why Cancer Trials Still Miss Older Adults

There is a need for trials mirroring real-world practices.

Dec 24, 2025 • Alyson Haslam

How To Study Drugs With Apparent Massive Effect Sizes, Still Using Randomization?

We proposed a trial design to answer this question.

Dec 16, 2025 • Timothée Olivier

Placebo First, Treatment Later: Is This Fair to Patients With Active Cancer?

In a new paper, we examined the randomized trials using inert control arms (mostly placebo only) leading to FDA approvals.

Dec 14, 2025 • Timothée Olivier

An Interview with Professor Rajshekhar Chakraborty: How Should We Care for Patients with High-Risk Smoldering Myeloma?

Daratumumab was approved in this setting in November 2025. Does this mean we should automatically prescribe it to all high-risk patients?

Dec 1, 2025 • Timothée Olivier

47:51

November 2025

When the Follow-Up Ends Too Soon: Rethinking Long-Term Benefit of Immunotherapy

Over the years, our research group has written a lot on immune checkpoint inhibitors (ICIs) in cancer, in part because of the excitement over durable…

Nov 28, 2025 • Alyson Haslam

Spotting informative censoring with longer follow-ups — the NADINA and NATALEE trials show two different patterns.

My new publication, “Identifying informative censoring from censoring patterns across successive follow-ups”, is out in the European Journal of Cancer…

Nov 22, 2025 • Timothée Olivier

Are fears of rising cancer in young adults exaggerated? A live talk with Ade Adamson

A recent JAMA Internal Medicine study sheds light on this question!

Nov 3, 2025 • Timothée Olivier

38:57

October 2025

The Iceberg Plot: A Visual I Conceived to Differentiate Tumor Biology from Treatment Effect.

I would like to emphasize a plot we published together with Vinay Prasad and Mark Lythgoe.

Oct 29, 2025 • Timothée Olivier

Post-ESMO 2025 on Adjuvant CDK4/6 Inhibitors after MonarchE and NATALEE Updates.

With nearly 40% of patients newly diagnosed with breast cancer potentially eligible, the stakes are high.

Oct 26, 2025 • Timothée Olivier

Reduce Toxicity and Save Money: The Paper and Website to Bookmark for Alternative Dosing in Oncology!

The website to boomark: https://oncdoc.org/

Oct 24, 2025 • Timothée Olivier

Solving Racial Inequalities in HLA-Restricted Therapies: Lessons from ESMO 2025.

Access to HLA-restricted therapy differs according to patients ethnicity, and should ideally be overcome.

Oct 21, 2025 • Timothée Olivier

Oncology “Me-Too” Drugs Compared With Original Drugs in Randomized Clinical Trials

This is the title of our recent JAMA Internal Medicine publication.

Oct 14, 2025 • Timothée Olivier

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts